Report of Foreign Issuer (6-k)
November 16 2015 - 6:12AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November, 2015
Commission File Number
Novogen
Limited
(Translation of registrants name into English)
16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F þ Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ¨
Note: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrants home country), or under the rules of the home country exchange on which the registrants securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrants security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ¨ No þ
If yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Novogen Limited (Registrant)
Lionel Mateo
Lionel Mateo
Company Secretary
Date 16 November 2015
|
|
|
|
|
ASX:NRT
NASDAQ:NVGN
Novogen Ltd (Company)
ABN 37 063 259 754
Capital Structure
Ordinary Shares on issue:
424 M
Board of Directors
Mr Ian Phillips MNZM
Interim Chairman
Mr Iain Ross Director
Acting CEO
Mr Steve Coffey Non-Executive Director
Mr John OConnor
Non-Executive Director
Prof Peter Gunning Non-Executive Director
Mr Bryce Carmine
Non-Executive Director |
|
MARKET RELEASE
16 November 2015
NOVOGEN SIGNS UNDERWRITING AGREEMENT FOR OUTSTANDING OPTIONS
Sydney, November 16, 2015 US-Australian drug discovery
company, Novogen Limited (ASX:NRT; NASDAQ: NVGN) today announced that it had signed an Underwriting Agreement with Lodge Partners to underwrite the outstanding options exercisable at $0.125 per option, which expire on 18 November 2015.
The exercise of options will provide the Company with an additional $690K (before costs),
which will reinforce the Companys financial position and will be directly allocated to help fund its Phase 1 clinical trial for Cantrixil, which is expected to start in 2016.
About Novogen Limited
Novogen is a public, Australian-US drug development company whose shares trade on both
The Australian Securities Exchange (NRT) and NASDAQ (NVGN). The Novogen Group includes US-based, CanTx Inc., a joint venture company with Yale University. Novogen has two drug technology platforms [the superbenzopyrans (SBPs) and anti-tropomyosins
(ATMs)] yielding drug candidates that are first-in-class with potential application across a range of degenerative diseases. Given the encouraging data from in vitro and in vivo preclinical proof-of-concept studies in the field of
oncology, the immediate focus is to undertake their respective toxicology programs. The target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. While the initial target pediatric indication for
Anisina has been identified as neuroblastoma, the Company is yet to identify the adult indication and are intending to open an all-comers Phase 1 trial initially based on the preclinical studies. For more information, please visit
www.novogen.com |
Media Enquiries:
Kym Robins
Marketing and Communications Director, Novogen Group
E: Kym.Robins@novogen.com / Ph: +61 (0) 2 9472 4109
Forward Looking Statement
This press release
contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such
words as expects, appear, intends, hopes, anticipates, believes, could, should, would, may, target,
evidences and estimates, and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to any statements relating to the Companys
drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Companys drug development program, including, but not limited to, Cantrixil, Anisina, Trilexium, and any other statements
that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production
and marketing of the Companys drug components, including, but not limited to, Cantrixil, Anisina, Trilexium, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate
therapeutic efficacy of the Companys drug compounds, including, but not limited to, Cantrixil, Anisina, Trilexium, that could slow or prevent products coming to market, the uncertainty of patent protection for the Companys intellectual
property or trade secrets, including, but not limited to, the intellectual property relating to Cantrixil, Anisina, Trilexium, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission
including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are based on managements current expectations, but actual results may differ materially due to various factions including those risks and uncertainties
mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Apr 2024 to May 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From May 2023 to May 2024